Stay updated with breaking news from Mohamed Eid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. FDA on Thursday blessed Lilly and Boehringer’s Jardiance with a label expansion to curb the risk of cardiovascular death and hospitalization for heart failure in adults. The move comes after the partners in November sent off an FDA application for the med to treat adults with heart failure independent of left ventricular ejection fraction.
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and...
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empaglifloz...
Empagliflozin reduced risk of CV death, hospitalization and slowed kidney function decline in adults with HF, LVEF over 40% regardless of CKD status.
/PRNewswire/ -- Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and...